WESTMINSTER, Colo. --(BUSINESS WIRE)--Jun. 26, 2024-- TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today
– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC – 4 mg dose demonstrated 3 of 3 patients achieving disease control, with one complete response in the liver (5L ICC), one partial response
DENVER --(BUSINESS WIRE)--May 24, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives Announced the appointment of Liselotte Hyveled to the Board of Directors Full year
– Accomplished industry veteran brings deep strategic and operational expertise DENVER --(BUSINESS WIRE)--May 7, 2024-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and
Call Scheduled for Wednesday, May 15, 2024 , at 9:00 a.m. ET DENVER --(BUSINESS WIRE)--May 6, 2024-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors,
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is expected to support execution of strategic expansion and fuel continued growth Including the full funding of
Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million , up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code Real-world data published on
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery – – A retrospective clinical study of the Pressure-Enabled Drug
DENVER --(BUSINESS WIRE)--Mar. 21, 2024-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from